Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trastuzumab deruxtecan proves active in HER2-mutated NSCLC

Publish date:: May 31, 2020

Key clinical point: Among patients with HER2-mutated non–small cell lung cancer, treatment with trastuzumab deruxtecan has yielded a high objective response rate and favorable progression-free survival.

Major finding: The confirmed overall response rate was 61.9%, and the median progression-free survival was 16.0 months.

Study details: Interim results of DESTINY-Lung01, a phase 2 study of 42 patients with HER2-mutated non–small cell lung cancer.

Disclosures: The study was sponsored by Daiichi Sankyo Inc. Dr. Smit disclosed relationships with Daiichi Sankyo and other companies.

Citation:

Smit EF et al. ASCO 2020, Abstract 9504.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,